Navigation Links
Jennerex Appoints James M. Burke, M.D. Vice President, Clinical Research
Date:2/22/2011

SAN FRANCISCO, Feb. 22, 2011 /PRNewswire/ -- Jennerex, Inc. (San Francisco), a clinical-stage cancer biotherapeutics company, today announced the appointment of James M. Burke, M.D. to the newly-created position of vice president, clinical research. Dr. Burke will be responsible for all global clinical research activities related to Jennerex pipeline compounds.

"Dr. Burke has been working with Jennerex in an advisory capacity as a clinical advisor for over a year, and has provided significant contributions to the strategic direction and clinical development of JX-594 for the treatment of liver cancer, and we look forward to bringing his expertise in-house," said David H. Kirn, M.D., president and chief executive officer of Jennerex. "In addition, as we advance our earlier stage pipeline products, Dr. Burke's direct clinical research experience using immunotherapeutics to treat multiple solid tumors will be instrumental as we pursue continued development of JX-929, JX-1395 and our next generation products."

Dr. Burke brings approximately 20 years of experience in basic and applied clinical science of genetic and immunotherapy.  His clinical research using immunotherapeutics including oncolytic viruses for the treatment of various cancers have advanced the understanding of the medical applications for oncolytic virus therapy. Prior to Jennerex, Dr. Burke was the Director of Cancer Research at Billings Clinic, where he was also a clinical investigator for JX-594. He had previously served as associate director of clinical research at Cell Genesys, Inc., where he was responsible for the development of the oncolytic adenovirus platform of agents and other gene therapy vaccines for the treatment of cancer and other diseases.  In addition, after completing his Hematology and Oncology Fellowship at UC San Francisco (UCSF), he was an attending physician at UCSF in the department of hematology and oncology. He received his M.D. from Georgetown University and his B.S. in biochemistry and cell biology from the University of California, San Diego. He is the author of more than 10 key publications and presentations detailing the use of gene therapy and oncolytic viruses to treat cancer. He is board certified in hematology, oncology and internal medicine.

About Jennerex

Jennerex, Inc. is a clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class, breakthrough targeted oncolytic products for cancer. The Company's lead product JX-594 is currently in two Phase 2 clinical trials in patients with primary liver cancer—an international, randomized, Phase 2 clinical trial, and a Phase 2 study of JX-594 in combination with sorafenib. Published studies designed to establish optimal dose levels and the safety profile of JX-594 have shown its ability to selectively target and cause destruction of a variety of common cancer types. JX-594 and other product candidates under development are designed to attack cancer tumors through three diverse mechanisms of action: the lysis of cancer cells through viral replication, the ablation of the blood supply to tumors through vascular targeting and destruction and the stimulation of the body's immune response against the cancer. Jennerex is headquartered in San Francisco and has related research and development operations in Ottawa, Canada and Pusan, South Korea. For more information about Jennerex, please visit www.jennerex.com.


'/>"/>
SOURCE Jennerex, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Jennerex and Transgene Enter Into an Exclusive Partnership for the Development and Commercialization of JX-594 for the Treatment of Cancers
2. Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million
3. Jennerex Reports Positive Phase 1 Results for JX-594 Administered Intravenously
4. Jennerex Adds Industry Veteran Paul Cleveland to Board of Directors
5. Jennerex Completes Over-Subscribed Series C Financing for Aggregate Gross Proceeds of Over $5.5 Million
6. Jennerex Closes $5 Million First Tranche of Series C Financing
7. Nature Reviews Publishes Article About Jennerexs Multi-Mechanistic Cancer Therapeutic
8. Jennerex Appoints Samantha Miller as Vice President of Corporate Development
9. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director
10. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
11. Amarin Corporation Appoints Industry Veteran Paul E. Huff as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ROTTERDAM, the Netherlands and LAGUNA HILLS, ... that The Institute of Cancer Research, London ... will use MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify ... high-risk trial known as MUK nine . The University ... this trial, which is partly funded by Myeloma UK, and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give ... Liposomal Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles ...
(Date:10/10/2017)... CALIFORNIA (PRWEB) , ... October 10, 2017 , ... ... technological innovation and business process optimization firm for the life sciences and healthcare ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation for ...
(Date:10/9/2017)... (PRWEB) , ... October 09, 2017 , ... ... a four-tiered line of medical marijuana products targeting the needs of consumers who ... packaging of Kindred takes place in Phoenix, Arizona. , As operators of two ...
Breaking Biology Technology:
(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:7/20/2017)... Delta (NYSE: DAL ) customers now can use ... Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at Reagan Washington ... Delta,s biometric boarding pass experience that ... integrated into the boarding process to allow eligible Delta SkyMiles Members who ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
Breaking Biology News(10 mins):